Alto Neuroscience's Breakthrough: Schizophrenia Drug ALTO-301 Rockets Towards Approval with FDA Fast Track!
Ovid Therapeutics Soars: A Game-Changing Deal with Takeda Propels Stock by 18%
Syngene International's Stock Slide: Unpacking the Decline and Market Impact